The antitumour activity of the prodrug N-L-leucyl-doxorubicin and its parent compound doxorubicin in human tumour xenografts

European Journal of Cancer

Volumn 34, Issue 10, 1998, Pages 1602-1606

  Breistol K ^c   Hendriks, H R ^a   Berger, D P ^c   Langdon, S P ^b   Fiebig, H H ^c   Fodstad, O ^c  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b WESTERN GENERAL HOSPITAL   (United Kingdom)

^c NONE

Author keywords

Antitumor activity; Doxorubicin; Human tumour xenografts; N L leucyl doxorubicin

Indexed keywords

DOXORUBICIN; LEURUBICIN; PRODRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CARDIOTOXICITY; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; ENZYME ACTIVITY; GROWTH INHIBITION; HYDROLYSIS; INTRAVENOUS DRUG ADMINISTRATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; TUMOR GROWTH; TUMOR XENOGRAFT;

ANIMALS; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CARCINOMA, NON-SMALL-CELL LUNG; CARCINOMA, SMALL CELL; CELL DIVISION; DOSE-RESPONSE RELATIONSHIP, DRUG; DOXORUBICIN; FEMALE; HUMANS; LUNG NEOPLASMS; MICE; MICE, INBRED BALB C; PRODRUGS; TRANSPLANTATION, HETEROLOGOUS;

EID: 0032169889     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0959-8049(98)00152-X     Document Type: Article

References (35)

1. 1. Arcamone F. Doxorubicin. New York, Academic Press, 1981.
2. 2. Weiss RB. The anthracyclines: will we ever find a better doxorubicin? [Review]. Semin Oncol 1992, 19(6), 670-686.
3. 3. Imondi AR, Della Torre P, Mazue G, et al. Dose - response relationship of dexrazoxane for prevention of doxorubicin-induced cardiotoxicity in mice, rats and dogs. Cancer Res 1996, 56(18), 4200-4204.
4. 4. Allen TM. Long-circulating (sterically stabilized) liposomes for targeted drug delivery. [Review]. Trends Pharmacol Sci 1994, 15(7), 215-220.
5. 5. Gill PS, Wernz J, Scadden DT, et al. Randomized phase III trial of liposomal daunorubicin versus doxorubicin, bleomycin, and vincristine in AIDS-related Kaposi's sarcoma. J Clin Oncol 1996, 14(8), 2353-2364.
6. 6. Sakakibara T, Chen FA, Kida H, et al. Doxorubicin encapsulated in sterically stabilized liposomes is superior to free drug or drug-containing conventional liposomes at suppressing growth and metastases of human lung tumor xenografts. Cancer Res 1996, 56(16), 3743-3746.
7. 7. Emanuel N, Kedar E, Bolotin EM, Smorodinsky NI, Barenholz Y. Preparation and characterization of doxorubicin-loaded sterically stabilized immunoliposomes. Pharm Res 1996, 13(3), 352-359.
8. 8. Doxorubicin liposome formulation gains marketing approval [news]. Am J Health Syst Pharm 1996, 53(2), 116.
9. 9. Houba PH, Leenders RG, Boven E, Scheeren JW, Pinedo HM, Haisma HJ. Characterization of novel anthracycline prodrugs activated by human beta-glucuronidase for use in antibody-directed enzyme prodrug therapy. Biochem Pharmacol 1996, 52(3), 455-463.
10. 10. Meyer DL, Law KL, Payne JK, et al. Site-specific prodrug activation by antibody-beta-lactamase conjugates: preclinical investigation of the efficacy and toxicity of doxorubicin delivered by antibody-directed catalysis. Bioconjug Chem 1995, 6(4), 440-446.
11. 11. Kerr DE, Schreiber GJ, Vrudhula VM, et al. Regressions and cures of melanoma xenografts following treatment with monoclonal antibody beta-lactamase conjugates in combination with anticancer prodrugs. Cancer Res 1995, 55(16), 3558-3563.
12. 12. Svensson HP, Vrudhula VM, Emswiler JE, et al. In vitro and in vivo activities of a doxorubicin prodrug in combination with monoclonal antibody beta-lactamase conjugates. Cancer Res 1995, 55(11), 2357-2365.
13. 13. Vrudhula VM, Svensson HP, Senter PD. Cephalosporin derivatives of doxorubicin as prodrugs for activation by monoclonal antibody-beta-lactamase conjugates. J Med Chem 1995, 38(8), 1380-1385.
14. 14. Bosslet K, Czech J, Hoffmann D. Tumor-selective prodrug activation by fusion protein-mediated catalysis. Cancer Res 1994, 54(8), 2151-2159.
15. 15. Mori A, Kennel SJ, Huang L. Immunotargeting of liposomes containing lipophilic antitumor prodrugs. Pharm Res 1993, 10(4), 507-514.
16. 16. Baurain R, Masquelier M, Deprez-De Campeneere D, Trouet A. Amino acid and dipeptide derivatives of daunorubicin. 2. Cellular pharmacology and antitumor activity on L1210 leukemic cells in vitro and in vivo. J Med Chem 1980, 23(11), 1171-1174.
17. 17. Masquelier M, Baurain R, Trouet A. Amino acid and dipeptide derivatives of daunorubicin. 1. Synthesis, physicochemical properties, and lysosomal digestion. J Med Chem 1980, 23(11), 1166-1170.
18. 18. Trouet A, Masquelier M, Baurain R, Deprez-De Campeneere D. A covalent linkage between daunorubicin and proteins that is stable in serum and reversible by lysosomal hydrolases, as required for a lysosomotropic drug-carrier conjugate: in vitro and in vivo studies. Proc Natl Acad Sci 1982, 79(2), 626-629.
19. 19. Briozzo P, Morisset M, Capony F, Rougeot C, Rochefort H. In vitro degradation of extracellular matrix with Mr 52,000 cathepsin D secreted by breast cancer cells. Cancer Res 1988, 48(13), 3688-3692.
20. 20. Keppler D, Fondaneche MC, Dalet-Fumeron V, Pagano M, Burtin P. Immunohistochemical and biochemical study of a cathepsin B-like proteinase in human colonic cancers. Cancer Res 1988, 48(23), 6855-6862.
21. 21. Maciewicz RA, Wardale RJ, Etherington DJ, Paraskeva C. Immunodetection of cathepsins B and L present in and secreted from human pre-malignant and malignant colorectal tumour cell lines. Int J Cancer 1989, 43(3), 478-486.
22. 22. de Jong J, Klein I, Bast A, van der Vijgh WJ. Analysis and pharmacokinetics of N-L-leucyldoxorubucin and metabolites in tissues of tumor-bearing BALB/c mice. Cancer Chemother Pharmacol 1992, 31(2), 156-160.
23. 23. de Jong J, Schoofs PR, Snabilie AM, Bast A, van der Vijgh WJ. The role of biotransformation in anthracycline-induced cardiotoxicity in mice. J Pharmacol Exp Ther 1993, 266(3), 1312-1320.
24. 24. Jaenke RS, Deprez-DeCampeneere D, Trouet A. Cardiotoxicity and comparative pharmacokinetics of six anthracyclines in the rabbit. Cancer Res 1980, 40(10), 3530-3536.
25. 25. Deprez-De Campeneere D, Baurain R, Trouet A. Accumulation and metabolism of new anthracycline derivatives in the heart after IV injection into mice. Cancer Chemother Pharmacol 1982, 8(2), 193-197.
26. 26. Zbinden G, DeCampeenere D, Baurain R. Preclinical assessment of the cardiotoxic potential of anthracycline antibiotics: N-L-leucyl-doxorubicin. Arch Toxicol Suppl 1991, 14, 107-117.
27. 27. Boven E, Hendriks HR, Erkelens CAM, Pinedo HM. The antitumor effects of the prodrug N-L-leucyl-doxorubicin and vinblastine-isoleucinate in human ovarian cancer xenografts. Br J Cancer 1992, 66, 1044-1047.
28. 28. Boven E, Winograd B, Berger DP, et al. Phase II preclinical drug screening in human tumor xenografts: A first European multicenter collaborative study. Cancer Res 1992, 52, 5940-5947.
29. 29. Langdon SP, Hendriks HR, Braakhuis BJ, et al. Preclinical phase II studies in human tumor xenografts: a European multicenter follow-up study. Ann Oncol 1994, 5(5), 415-422.
30. 30. Boven E, Schlüper HMM, Erkelens CAM, Pinedo HM. Doxorubicin compared with related compounds in a nude mouse model for human ovarian cancer. Eur J Cancer 1990, 26, 983-986.
31. 31. Boven E, de Jong J, Kuiper CM, et al. Relationship between the tumor tissue pharmacokinetics and the antiproliferative effects of anthracyclines and their metabolites. Eur J Cancer 1996, 32A(8), 1382-1387.
32. 32. de Jong J, Geijssen GJ, Munniksma CN, Vermorken JB, van der Vijgh WJ. Plasma pharmacokinetics and pharmacodynamics of a new prodrug N-L-leucyl-doxorubicin and its metabolites in a phase I clinical trial. J Clin Oncol 1992, 10(12), 1897-1906.
33. 33. Canal P, Robert J, Ramon M, et al. Human pharmacokinetics of N-L-leucyl-doxorubicin, a new anthracycline derivative, and its correlation with clinical toxicities. Clin Pharmacol Ther 1992, 51(3), 249-259.
34. 34. Winograd B, Boven E, Lobbezoo MW, Pinedo HM. Human tumor xenografts in the nude mouse and their value as test models in anticancer drug development. [Review]. In Vivo 1987, 1(1), 1-13.
35. 35. Boven E, Winograd B, Fodstad Ø, Lobbezoo MW, Pinedo HM. Preclinical phase II studies in human tumor lines: a European multicenter study. Eur J Cancer Clin Oncol 1988, 24(3), 567-573.